New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
09:59 EDTEPE, SBNY, MGLN, NCI, DYAX, BCRX, VRTSOn The Fly: Analyst Initiation Summary
Magellan Health (MGLN) initiated with a Market Perform at Leerink... Virtus Investment Partners (VRTS) initiated with a Neutral at BofA/Merrill... Signature Bank (SBNY) coverage resumed with a Buy at Goldman... Dyax (DYAX) initiated with an Outperform at Oppenheimer... BioCryst (BCRX) initiated with a Perform at Oppenheimer... Navigant Consulting (NCI) initiated with a Buy at UBS... EP Energy (EPE) initiated with an Equal Weight at Morgan Stanley.
News For MGLN;VRTS;DYAX;SBNY;BCRX;NCI;EPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
15:17 EDTBCRXBioCryst management to meet with JPMorgan
Subscribe for More Information
May 13, 2015
10:01 EDTMGLNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:00 EDTBCRXBioCryst initiates Phase 1 clinical trial of angioedema candidate
Subscribe for More Information
05:36 EDTMGLNMagellan Health upgraded to Buy from Hold at Jefferies
Jefferies upgraded Magellan Health to Buy with a $78 price target saying the company's path to 20% earnings growth is improving.
May 12, 2015
07:52 EDTDYAXLeerink to hold a tour
Subscribe for More Information
May 11, 2015
09:59 EDTDYAXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:02 EDTVRTSVirtus Investment Partners reports assets under management $54.8B at March 31
Subscribe for More Information
08:01 EDTVRTSVirtus Investment Partners reports Q1 adjusted EPS $2.22, consensus $2.40
Reports Q1 revenue $103.8M, consensus $104.85M. Reports Q1 adjusted revenue $79.7M.
06:46 EDTDYAXDyax downgraded to Perform from Outperform at Oppenheimer
Subscribe for More Information
May 8, 2015
10:01 EDTEPEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:47 EDTBCRXBioCryst sees FY15 net operating cash use $65M-$80M
Subscribe for More Information
09:47 EDTBCRXBioCryst says OPuS-2 clinical trial proceeding as planned
Subscribe for More Information
09:16 EDTBCRXBioCryst sees FY15 net operating cash use $65M-$80M
Subscribe for More Information
09:15 EDTBCRXBioCryst says OPuS-2 clinical trial proceeding as planned
Subscribe for More Information
09:15 EDTBCRXBioCryst reports Q1 EPS (21c), consensus (25c)
Reports Q1 revenue $6.83M, consensus $4.3M
06:13 EDTEPEEP Energy downgraded to Neutral from Buy at Guggenheim
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use